Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Abbreviations: AFASAK 5 Atrial Fibrillation, Aspirin, Anticoagulation; AMI 5 acute myocardial infarction; AF 5 atrial fibrillation; CARS 5 Coumadin Aspirin Reinfarction Study; CI 5 confidence interval; DVT 5 deep vein thrombosis; INR 5 international normalized ratio; IRP 5 international reference preparation; ISI 5 international sensitivity index; MI 5 myocardial infarction; PE 5 pulmonary embolism; PT 5 prothrombin time; SPAF 5 Stroke Prevention in Atrial Fibrillation; WHO 5 World Health Organization

[1]  Sonia S Anand,et al.  Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. , 1999, JAMA.

[2]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[3]  M. Weitekamp,et al.  Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. , 1983, JAMA.

[4]  S. M. Garabedian-Ruffalo,et al.  Cost-Justification of a Clinical Pharmacist-Managed Anticoagulation Clinic , 1985, Drug Intelligence & Clinical Pharmacy.

[5]  L. Poller,et al.  Prospective comparative study of computer programs used for management of warfarin. , 1993, Journal of clinical pathology.

[6]  O'Reilly Ra,et al.  Studies on the interaction of warfarin and clofibrate in man. , 1972 .

[7]  D. P. Bentley,et al.  Effective Reversal of Warfarin-lnduced Excessive Anticoagulation with Low Dose Mtamin K1 , 1992, Thrombosis and Haemostasis.

[8]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[9]  G. Albers,et al.  Atrial fibrillation and stroke. Three new studies, three remaining questions. , 1994, Archives of internal medicine.

[10]  J. Heit,et al.  RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group. , 1994, The Journal of bone and joint surgery. American volume.

[11]  Jespersen,et al.  A comparison of artificially‐depleted, lyophilized coumarin and fresh coumarin plasmas in thromboplastin calibration , 1998, British journal of haematology.

[12]  J. Avorn,et al.  Aging and the Anticoagulant Response to Warfarin Therapy , 1992, Annals of Internal Medicine.

[13]  Donald Martin,et al.  Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study , 1993, Annals of Internal Medicine.

[14]  J. Ansell,et al.  Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. , 1996, American heart journal.

[15]  T. Meade.  Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease. , 1990, The American journal of cardiology.

[16]  A. Manoharan.  Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants , 1998, Annals of Internal Medicine.

[17]  D. Brogan,et al.  Proficiency testing and standardization of prothrombin time: effect of thromboplastin, instrumentation, and plasma. , 1984, American journal of clinical pathology.

[18]  S. McCurdy,et al.  Accuracy and precision of a portable anticoagulation monitor in a clinical setting. , 1992, Archives of internal medicine.

[19]  E. Svenungsson,et al.  Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. , 1998, The American journal of medicine.

[20]  R. Ebert,et al.  Anticoagulants in acute myocardial infarction: results of a cooperative clinical trial , 1973 .

[21]  P. Höglund,et al.  Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men , 1989, Therapeutic drug monitoring.

[22]  G. Raskob,et al.  Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. , 1990, The New England journal of medicine.

[23]  E. Garelli,et al.  Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[24]  O. Malhotra.  Dicoumarol-induced prothrombins containing 6, 7, and 8 gamma-carboxyglutamic acid residues: isolation and characterization. , 1989, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[25]  T. Ortel,et al.  Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants , 1997, Annals of Internal Medicine.

[26]  C. Peck,et al.  Hereditary warfarin resistance. Investigation of a rare phenomenon. , 1985, Archives of internal medicine.

[27]  D. Sherman,et al.  Antithrombotic therapy for cerebrovascular disorders. , 1989, Chest.

[28]  T B Kirkwood,et al.  Calibration of Reference Thromboplastins and Standardisation of the Prothrombin Time Ratio , 1983, Thrombosis and Haemostasis.

[29]  M. Hoag,et al.  HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED. , 1964, The New England journal of medicine.

[30]  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.

[31]  J. Pettifor,et al.  Congenital malformations associated with the administration of oral anticoagulants during pregnancy. , 1975, The Journal of pediatrics.

[32]  D. Skinner,et al.  Warfarin necrosis of the skin and subcutaneous tissue of the male external genitalia. , 1983, The Journal of urology.

[33]  G. Nelsestuen.  Role of gamma-carboxyglutamic acid. An unusual protein transition required for the calcium-dependent binding of prothrombin to phospholipid. , 1976, The Journal of biological chemistry.

[34]  B. Walters,et al.  Prophylaxis of thromboembolism in pregnancy: an alternative , 1985, British journal of obstetrics and gynaecology.

[35]  P. Delmas,et al.  Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. , 1992, Endocrinology.

[36]  T. Meade,et al.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk , 1998, The Lancet.

[37]  P Smith,et al.  The effect of warfarin on mortality and reinfarction after myocardial infarction. , 1990, The New England journal of medicine.

[38]  A. Breckenridge.  Oral anticoagulant drugs: pharmacokinetic aspects. , 1978, Seminars in hematology (Print).

[39]  G. Raskob,et al.  A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. , 1993, The New England journal of medicine.

[40]  F. Verheugt,et al.  A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin , 1997, Annals of neurology.

[41]  R. K. Richards.  INFLUENCE OF FEVER UPON THE ACTION OF 3,3'-METHYLENE-BIS-(4-HYDROXYCOUMARIN) (DICUMAROL). , 1943, Science.

[42]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[43]  P. J. Ryan,et al.  Computer control of anticoagulant dose for therapeutic management. , 1989, BMJ.

[44]  P. Prandoni,et al.  Deep Venous Thrombosis and Lupus Anticoagulant , 1996, Thrombosis and Haemostasis.

[45]  L. Poller,et al.  Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis , 1978, British medical journal.

[46]  J. Hirsh,et al.  Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. , 1996, The Journal of laboratory and clinical medicine.

[47]  L. Poller,et al.  The correction of coagulometer effects on international normalized ratios: a multicentre evaluation , 1994, British journal of haematology.

[48]  A. J. Robinson,et al.  Studies on the interaction of warfarin and clofibrate in man. , 1972, Thrombosis et diathesis haemorrhagica.

[49]  Leah M. Moore,et al.  Outcome Analysis of a Pharmacist‐Managed Anticoagulation Service , 1995, Pharmacotherapy.

[50]  J. Soria,et al.  Successful Progressive Anticoagulation in a Severe Protein C Deficiency and Previous Skin Necrosis at the Initiation of Oral Anticoagulant Treatment , 1984, Thrombosis and Haemostasis.

[51]  J. Suttie,et al.  Evidence that warfarin anticoagulant action involves two distinct reductase activities. , 1982, The Journal of biological chemistry.

[52]  J. Alpert,et al.  Long-term anticoagulant therapy after acute myocardial infarction. , 1985, American heart journal.

[53]  J C Forfar,et al.  Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. , 1982, American heart journal.

[54]  R. O'Reilly.  Studies on the optical enantiomorphs of warfarin in man. , 1974, Clinical pharmacology and therapeutics.

[55]  W. Ageno,et al.  A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. , 1998, Thrombosis research.

[56]  P. Minor,et al.  WHO Expert Committee on Biological Standardization. , 2004, World Health Organization technical report series.

[57]  W. Bell.  Acetaminophen and Warfarin: Undesirable Synergy , 1998 .

[58]  P. Price,et al.  Sequence of the precursor to rat bone gamma-carboxyglutamic acid protein that accumulates in warfarin-treated osteosarcoma cells. , 1985, The Journal of biological chemistry.

[59]  L. Poller,et al.  Dosage and control of oral anticoagulants: an international collaborative survey , 1982, British journal of haematology.

[60]  L Goldman,et al.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. , 1989, The American journal of medicine.

[61]  G. Lip,et al.  Anticoagulation and atrial fibrillation , 2001, Postgraduate medical journal.

[62]  M. Lockshin.  Thrombosis in the antiphospholipid-antibody syndrome. , 1995, The New England journal of medicine.

[63]  A. Breckenridge,et al.  Stereoselective interaction between the R enantiomer of warfarin and cimetidine. , 1986, British journal of clinical pharmacology.

[64]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[65]  A. Breckenridge,et al.  Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man , 1974, Clinical pharmacology and therapy.

[66]  E. Sellers,et al.  Drug interactions with coumarin anticoagulants. 2. , 1971, The New England journal of medicine.

[67]  M Gent,et al.  Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. , 1979, The New England journal of medicine.

[68]  A. MacNicoll,et al.  ASPECTS OF ANTICOAGULANT ACTION: A Review of the Pharmacology, Metabolism and Toxicology of Warfarin and Congeners , 1987, Reviews on drug metabolism and drug interactions.

[69]  E. Kruithof,et al.  Necrosis of skin induced by coumarin in a patient deficient in protein S. , 1989, BMJ.

[70]  M. Ray,et al.  The Dependence of the International Sensitivity Index on the Coagulometer Used to Perform the Prothrombin Time , 1990, Thrombosis and Haemostasis.

[71]  J. Cairns,et al.  Antithrombotic agents in coronary artery disease. , 1989, Chest.

[72]  R. Reilly.  Studies on the optical enantiomorphs of warfarin in man , 1974 .

[73]  R. O'reilly,et al.  Vitamin K and the oral anticoagulant drugs. , 1976, Annual Review of Medicine.

[74]  E. Minar,et al.  The Risk of Early Recurrent Venous Thromboembolism after Oral Anticoagulant Therapy in Patients with the G20210A Transition in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[75]  P. Wyld,et al.  Computer dosing in anticoagulant clinics--the way forward? , 1988, Clinical and laboratory haematology.

[76]  R. L. Ruffalo,et al.  Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. , 1985, American journal of hospital pharmacy.

[77]  S. Feffer,et al.  Hereditary warfarin resistance. , 1994, Southern medical journal.

[78]  G. Perego,et al.  Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate. , 1996, European heart journal.

[79]  I. Wright,et al.  Myocardial infarction and its treatment with anticoagulants; summary of findings in 1031 cases. , 1954, Lancet.

[80]  R. Bertina,et al.  Protein C and the Development of Skin Necrosis During Anticoagulant Therapy , 1983, Thrombosis and Haemostasis.

[81]  B. Lyle,et al.  Vitamin K deficiency from dietary vitamin K restriction in humans. , 1988, The American journal of clinical nutrition.

[82]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[83]  L. Poller.  European concerted action on anticoagulation (ECAA). , 1996, Haemostasis.

[84]  R. Rosenberg,et al.  A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. , 1977, Biochimica et biophysica acta.

[85]  L. Poller,et al.  Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers. , 1990, Journal of clinical pathology.

[86]  Lorentz Sm,et al.  Potentiation of warfarin anticoagulation by topical testosterone ointment. , 1985 .

[87]  A. Zivelin,et al.  Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. , 1993, The Journal of clinical investigation.

[88]  O'Reilly Ra,et al.  "Resistance" to warfarin due to unrecognized vitamin K supplementation. , 1980 .

[89]  M. Kazama,et al.  Evaluation of International Normalized Ratios by a Controlled Field Survey with 4 Different Thromboplastin Reagents , 1990, Thrombosis and Haemostasis.

[90]  R. O'Reilly.  Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. , 1981, Archives of Internal Medicine.

[91]  E. Duncan,et al.  Effect of Concentration of Trisodium Citrate Anticoagulant on Calculation of the International Normalised Ratio and the International Sensitivity Index of Thromboplastin , 1994, Thrombosis and Haemostasis.

[92]  O. Linder,et al.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. , 1997, The New England journal of medicine.

[93]  P. Maccallum,et al.  Effects of Fixed Minidose Warfarin on Coagulation and Fibrinolysis Following Major Gynaecological Surgery , 1990, Thrombosis and Haemostasis.

[94]  S. Gitel,et al.  Warfarin. From bedside to bench. , 1984, The New England journal of medicine.

[95]  A. Wycherley,et al.  SAFETY AND EFFICACY OF WARFARIN STARTED EARLY AFTER SUBMASSIVE VENOUS THROMBOSIS OR PULMONARY EMBOLISM , 1986, The Lancet.

[96]  J. Kelly,et al.  Clinical Pharmacokinetics of Oral Anticoagulants , 1979, Clinical pharmacokinetics.

[97]  W. Hauser,et al.  Complications of long‐term anticoagulation , 1988, Annals of neurology.

[98]  A. Gallus,et al.  Trial of different intensities of anticoagulation in patients with prosthetic heart valves. , 1990, The New England journal of medicine.

[99]  V. Fuster,et al.  Anticoagulation clinics and the monitoring of anticoagulant therapy. , 1988, International journal of cardiology.

[100]  J. Hirsh.  Substandard monitoring of warfarin in North America. Time for change. , 1992, Archives of internal medicine.

[101]  A. James,et al.  Experience with a computer-assisted anticoagulant clinic. , 1989, Clinical and laboratory haematology.

[102]  D. Howie,et al.  Prevention of venous thrombosis with minidose warfarin after joint replacement. , 1991, BMJ.

[103]  E. Sellers,et al.  Drug Interactions with Coumarin Anticoagulants , 1971 .

[104]  C. Gray.  Acetaminophen and risk factors for excess anticoagulation with warfarin. , 1998, JAMA.

[105]  S. Ahmad.  Drug interactions with oral anticoagulants , 1980, Postgraduate medicine.

[106]  T. Ortel,et al.  Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic Warfarin therapy , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[107]  P. M. Aggeler,et al.  Determinants of the response to oral anticoagulant drugs in man. , 1970, Pharmacological reviews.

[108]  T. Pullar.  Interaction of ibuprofen and warfarin on primary haemostasis. , 1989, British journal of rheumatology.

[109]  M Gent,et al.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.

[110]  R. Conte,et al.  Nine-year experience with a pharmacist-managed anticoagulation clinic. , 1986, American journal of hospital pharmacy.

[111]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[112]  M. Kovacs,et al.  Assessment of the Validity of the INR System for Patients with Liver Impairment , 1994, Thrombosis and Haemostasis.

[113]  N. Zauber,et al.  Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. , 1986, Annals of internal medicine.

[114]  P. Maccallum,et al.  Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study. , 1990, British heart journal.

[115]  M G Amato,et al.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. , 1998, Archives of internal medicine.

[116]  J. Udall.  Human sources and absorption of vitamin K in relation to anticoagulation stability. , 1965, JAMA.

[117]  D A Taberner,et al.  Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR) , 1989, Journal of clinical pathology.

[118]  H. Bussey,et al.  Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. , 1992, Archives of internal medicine.

[119]  J. Hirsh,et al.  A comparison of lyophilized artificially depleted plasmas and lyophilized plasmas from patients receiving warfarin in correcting for coagulometer effects on international normalized ratios. , 1995, American journal of clinical pathology.

[120]  E. Myhre,et al.  Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. , 1980, American heart journal.

[121]  E. Gottfried,et al.  Failure of the International Normalized Ratio to generate consistent results within a local medical community. , 1993, American journal of clinical pathology.

[122]  H. Bussey,et al.  A Review of Enzyme Induction of Warfarin Metabolism with Recommendations for Patient Management , 1997, Pharmacotherapy.

[123]  E. van der Velde,et al.  The Effect of Some Instruments for Prothrombin Time Testing on the International Sensitivity Index (ISI) of Two Rabbit Tissue Thromboplastin Reagents , 1989, Thrombosis and Haemostasis.

[124]  R Wilson,et al.  Computer assisted management of warfarin treatment. , 1984, British medical journal.

[125]  M. Sakon,et al.  Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor. , 1992, Thrombosis research.

[126]  A. Laupacis,et al.  A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. , 1993, The New England journal of medicine.

[127]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.

[128]  J. Ansell,et al.  Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. , 1989, Archives of internal medicine.

[129]  R. Pauli,et al.  Maternal and fetal sequelae of anticoagulation during pregnancy. , 1980, The American journal of medicine.

[130]  D. Mungall,et al.  A novel whole blood capillary technic for measuring the prothrombin time. , 1987, American journal of clinical pathology.

[131]  T. A. Harper,et al.  The "therapeutic range" of the one-stage prothrombin time in the control of anticoagulant therapy: the effect of different thromboplastin preparations. , 1971, Canadian Medical Association journal.

[132]  L. Poller,et al.  Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. , 1987, British medical journal.

[133]  P. Bonini,et al.  Comparison of two automated coagulometers and the manual tilt-tube method for the determination of prothrombin time. , 1989, American journal of clinical pathology.

[134]  P. Mannucci,et al.  Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy , 1984, British journal of haematology.

[135]  M. Rhee,et al.  Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3-epoxide: evidence for multiple pathways of hydroxyvitamin K formation. , 1988, Archives of biochemistry and biophysics.

[136]  R. O'Reilly,et al.  "Resistance" to warfarin due to unrecognized vitamin K supplementation. , 1980, The New England journal of medicine.

[137]  D. Mungall,et al.  Aging and warfarin therapy. , 1992, Annals of internal medicine.

[138]  J. Vandenbroucke,et al.  Optimal oral anticoagulant therapy in patients with mechanical heart valves. , 1995, The New England journal of medicine.

[139]  J. Hirsh,et al.  The optimal intensity of oral anticoagulant therapy. , 1987, JAMA.

[140]  V. Fuster,et al.  Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. , 1983, The American journal of cardiology.

[141]  A. Turpie.  Anticoagulant therapy after acute myocardial infarction. , 1990, The American journal of cardiology.

[142]  E. Loeliger.  ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. , 1985, Haematologica.

[143]  R. Weibert,et al.  Evaluation of a capillary whole-blood prothrombin time measurement system. , 1989, Clinical pharmacy.

[144]  P. M. Aggeler,et al.  HEREDITARY RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS IN MAN AND RAT * , 1968, Annals of the New York Academy of Sciences.

[145]  G. Clark,et al.  The Safety and Effectiveness of Long‐Term Warfarin Therapy in an Anticoagulation Clinic , 1989, Pharmacotherapy.

[146]  J. Jespersen,et al.  The European Concerted Action on Anticoagulation (ECAA): Field Studies of Coagulometer Effects on the ISI of ECAA Thromboplastins , 1998, Thrombosis and Haemostasis.

[147]  U. Vasan,et al.  Is warfarin sodium contraindicated in the lactating mother? , 1983, The Journal of pediatrics.

[148]  L. Poller,et al.  Effect of automation on prothrombin time test in NEQAS surveys. , 1989, Journal of clinical pathology.

[149]  Kempin Sj.  Warfarin resistance caused by broccoli. , 1983 .

[150]  B. Gersh,et al.  Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. , 1995, Mayo Clinic proceedings.

[151]  N. A. Schmidt,et al.  Correction of instrument- and reagent-based differences in determination of the International Normalized Ratio (INR) for monitoring anticoagulant therapy. , 1989, Clinical chemistry.

[152]  M. Samama,et al.  Laboratory monitoring of oral anticoagulant therapy. , 1994, Clinics in laboratory medicine.

[153]  J. Hirsh,et al.  A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. , 1989, Archives of internal medicine.

[154]  J. Suttie,et al.  Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. , 1978, Biochemistry.

[155]  A. Breckenridge,et al.  Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. , 1984, British journal of clinical pharmacology.

[156]  Coumadin Aspirin Reinfarction Study Investigators.  Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction , 1997, The Lancet.

[157]  J. Hirsh,et al.  Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. , 1982, The New England journal of medicine.

[158]  A. Breckenridge,et al.  The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. , 1988, British journal of clinical pharmacology.

[159]  D. E. Wood,et al.  Discrepant Results in INR Testing , 1994, Thrombosis and Haemostasis.

[160]  T. Barbui,et al.  Thrombotic and Hemorrhagic Complications in Patients with Mechanical Heart Valve Prosthesis Attending an Anticoagulation Clinic , 1993, Thrombosis and Haemostasis.

[161]  C. Francis,et al.  Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. , 1983, JAMA.

[162]  G. Eskeland.  Prevention of venous thrombosis and pulmonary embolism in injured patients. , 1962, Lancet.

[163]  D. Tweedle.  Letter: Intravenous fat. , 1976, Lancet.

[164]  T. Baglin,et al.  Evaluation of the Ciba Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation. , 1991, Journal of clinical pathology.

[165]  L. Poller.  Laboratory control of oral anticoagulants. , 1987, British medical journal.

[166]  K. Mann,et al.  Differentiation of metal ion-induced transitions of prothrombin fragment 1. , 1977, The Journal of biological chemistry.

[167]  K. Mann,et al.  The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins. , 1985, The Journal of biological chemistry.

[168]  J. Hirsh.  Is the dose of warfarin prescribed by American physicians unnecessarily high? , 1987, Archives of internal medicine.

[169]  H. Fraser,et al.  Clinically significant hemorrhage due to warfarin-carbamazepine interaction. , 1990, Southern medical journal.

[170]  O. Malhotra.  Dicoumarol-induced 9-gamma-carboxyglutamic acid prothrombin: isolation and comparison with the 6-, 7-, 8-, and 10-gamma-carboxyglutamic acid isomers. , 1990, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[171]  P. Mannucci,et al.  Determination of the International Sensitivity Index of a New Near-Patient Testing Device to Monitor Oral Anticoagulant Therapy , 1997, Thrombosis and Haemostasis.

[172]  P. Mannucci,et al.  Status of Present and Candidate International Reference Preparations (IRP) of Thromboplastin for the Prothrombin Time , 1993, Thrombosis and Haemostasis.

[173]  G. Raskob,et al.  Hemorrhagic complications of long-term anticoagulant therapy. , 1986, Chest.

[174]  P. Caraballo,et al.  Long-term use of oral anticoagulants and the risk of fracture. , 1999, Archives of internal medicine.

[175]  J B Lian,et al.  Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. , 1989, Physiological reviews.

[176]  R. O'Reilly.  Interaction of chronic daily warfarin therapy and rifampin. , 1975, Annals of internal medicine.

[177]  G. Cooper,et al.  One-stage prothrombin time survey. , 1970, American journal of clinical pathology.

[178]  J. Hirsh,et al.  Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. , 1993, Archives of internal medicine.

[179]  A. D’Angelo,et al.  Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants. , 1996, Annales de medecine interne.

[180]  J. Hirsh.  The optimal duration of anticoagulant therapy for venous thrombosis. , 1995, The New England journal of medicine.

[181]  R. White,et al.  Temporary Discontinuation of Warfarin Therapy: Changes in the International Normalized Ratio , 1995, Annals of Internal Medicine.

[182]  J. Vandenbroucke,et al.  Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. , 1993, Archives of internal medicine.

[183]  J. Hirsh,et al.  A comparison of lyophilized artificially depleted plasmas and lyophilized plasmas from warfarin treated patients in correcting for coagulometer effects on international normalized ratios , 1995 .

[184]  A. Parke,et al.  Thrombosis in the antiphospholipid-antibody syndrome. , 1995, The New England journal of medicine.

[185]  M. Verstraete,et al.  Use of Different Tissue Thromboplastins in the Control of Anticoagulant Therapy , 1957, Circulation.

[186]  S. Rapaport,et al.  The International Normalized Ratio (INR) for Monitoring Warfarin Therapy: Reliability and Relation to Other Monitoring Methods , 1994, Annals of Internal Medicine.

[187]  L. Poller.  A Simple Nomogram for the Derivation of International Normalised Ratios for the Standardisation of Prothrombin Times , 1988, Thrombosis and Haemostasis.

[188]  P. Fernlund,et al.  Vitamin K dependent modifications of glutamic acid residues in prothrombin. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[189]  J. Emmerich,et al.  Anticardiolipin Antibodies and Recurrent Thromboembolism , 1997, Thrombosis and Haemostasis.

[190]  G. Staddon,et al.  Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. , 1991, BMJ.

[191]  C. Francis,et al.  Comparison of Native Prothrombin Antigen With the Prothrombin Time for Monitoring Oral Anticoagulant Prophylaxis , 1993, Circulation.

[192]  L. Poller,et al.  The reliability of international normalized ratios during short-term oral anticoagulant treatment. , 1988, Clinical and laboratory haematology.

[193]  S. Rapaport,et al.  Correction of Excessive Anticoagulation with Low-Dose Oral Vitamin K1 , 1997, Annals of Internal Medicine.

[194]  Monitoring effects of oral anticoagulants during treatment with heparin. , 1984, British medical journal.

[195]  A Drapkin,et al.  Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. , 1972, JAMA.

[196]  B. Diquet,et al.  The warfarin-cimetidine interaction: stereochemical considerations. , 1986, British journal of clinical pharmacology.

[197]  B. Oberhardt,et al.  Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis. , 1991, Clinical chemistry.

[198]  W. Trager,et al.  Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans , 1987, Clinical pharmacology and therapeutics.

[199]  P. Price.  Role of vitamin-K-dependent proteins in bone metabolism. , 1988, Annual review of nutrition.

[200]  A. Clarke,et al.  Warfarin dosage and vitamin K in Osmolite. , 1980, Annals of internal medicine.

[201]  Heather L. Heiman,et al.  Contributions Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation , 2001 .

[202]  P. Agostoni,et al.  The discriminatory value of the P(A-a)O2 during exercise in the detection of asbestosis in asbestos exposed workers. , 1989, Chest.

[203]  D. Graham,et al.  Aspirin and the stomach. , 1986, Annals of internal medicine.

[204]  A. Breckenridge,et al.  Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. , 1974, The Journal of clinical investigation.

[205]  P. Benotti,et al.  Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.

[206]  S. Booth,et al.  Dietary Vitamin and Stability of Oral Anticoagulation: Proposal of a Diet with Constant Vitamin K1 Content , 1997, Thrombosis and Haemostasis.

[207]  N. Anastas,et al.  Comparison of Thromboplastins Using the ISI and INR System , 1990, Pathology.

[208]  Z. J. Lipowski.  Letter: Psychosomatic medicine. , 1974, Lancet.

[209]  D. P. Bentley,et al.  Flexible induction dose regimen for warfarin and prediction of maintenance dose. , 1984, British medical journal.

[210]  M. Rosove,et al.  Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients , 1992, Annals of Internal Medicine.

[211]  L. Fish,et al.  Long-term patient self-management of oral anticoagulation. , 1995, Archives of internal medicine.

[212]  P. Majerus,et al.  The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. , 1975, The Journal of clinical investigation.

[213]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[214]  E. Hylek,et al.  Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.

[215]  C. Alfrey,et al.  The hemostatic defect produced by carbenicillin. , 1974, The New England journal of medicine.

[216]  U. Albrechtsson,et al.  NEED FOR LONG-TERM ANTICOAGULANT TREATMENT IN SYMPTOMATIC CALF-VEIN THROMBOSIS , 1985, The Lancet.

[217]  M. Moia,et al.  Thrombotic Events during Oral Anticoagulant Treatment: Results of the Inception-cohort, Prospective, Collaborative ISCOAT Study , 1997, Thrombosis and Haemostasis.

[218]  K. High,et al.  A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. , 1996, The Journal of clinical investigation.

[219]  M. Schemper,et al.  INFLUENCE OF POSTOPERATIVE ANTICOAGULANT TREATMENT ON PATIENT SURVIVAL AFTER FEMOROPOPLITEAL VEIN BYPASS SURGERY , 1988, The Lancet.

[220]  P. Maccallum,et al.  Minidose Warfarin and Failure to Prevent Deep Vein Thrombosis After Joint Replacement Surgery Despite Inhibiting the Postoperative Rise in Plasminogen Activator Inhibitor Activity , 1995 .

[221]  A Correction , 1911 .

[222]  Loeliger Ea,et al.  Pharmacological aspects of vitamin K1. A clinical and experimental study in man. , 1968 .

[223]  M. Crowther,et al.  Low-dose Oral Vitamin K Reliably Reverses Over-anticoagulation due to Warfarin , 1998, Thrombosis and Haemostasis.

[224]  R. O'Reilly.  The stereoselective interaction of warfarin and metronidazole in man. , 1976, The New England journal of medicine.

[225]  J. Hirsh,et al.  Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer , 1994, The Lancet.

[226]  B. Furie,et al.  Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. , 1990, Blood.

[227]  J. Oldenburg,et al.  Missense mutations at ALA‐10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy , 1997, British journal of haematology.

[228]  M. Klauber,et al.  Effect of erythromycin in patients receiving long-term warfarin therapy. , 1989, Clinical pharmacy.

[229]  J. Hirsh,et al.  Interactions of Warfarin with Drugs and Food , 1994, Annals of Internal Medicine.

[230]  S. Zucker,et al.  Standardization of laboratory tests for controlling anticoagulent therapy. , 1970, American journal of clinical pathology.

[231]  G. Hughes,et al.  The management of thrombosis in the antiphospholipid-antibody syndrome. , 1995, The New England journal of medicine.

[232]  A. James,et al.  Computer control of anticoagulant dose , 1989, BMJ.

[233]  H. White,et al.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .

[234]  J. Hirsh,et al.  The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. An international multicenter study. , 1995, American journal of clinical pathology.

[235]  J. C. Owens,et al.  Effect of sodium dextrothyroxine in patients receiving anticoagulants. , 1962, The New England journal of medicine.

[236]  J. Souto,et al.  Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study. , 1996, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[237]  L. Poller,et al.  Survey of prothrombin time in National External Quality Assessment Scheme exercises (1980-87). , 1988, Journal of clinical pathology.

[238]  J. Ansell,et al.  Consensus Guidelines for Coordinated Outpatient Oral Anticoagulation Therapy Management , 1997, The Annals of pharmacotherapy.

[239]  J. Hirsh,et al.  RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENT , 1988, The Lancet.

[240]  E. Gurfinkel,et al.  Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. , 1991, The Journal of thoracic and cardiovascular surgery.

[241]  S. Walker,et al.  The Effects of Acetaminophen on Pharmacokinetics and Pharmacodynamics of Warfarin , 1999, Journal of clinical pharmacology.

[242]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .

[243]  E. Mascha,et al.  Accuracy of laboratory and portable monitor international normalized ratio determinations. Comparison with a criterion standard. , 1995, Archives of internal medicine.

[244]  J. Hirsh,et al.  Management of anticoagulation before and after elective surgery. , 1997, The New England journal of medicine.

[245]  M. Verstraete,et al.  Questions and Answers on Prothrombin Time Standardisation in Oral Anticoagulant Control , 1985, Thrombosis and Haemostasis.

[246]  S. Sevitt,et al.  Prevention of venous thrombosis and pulmonary embolism in injured patients. A trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur. , 1959, Lancet.

[247]  B. Vidne,et al.  A self control method for long term anticoagulation therapy. , 1974, The Journal of cardiovascular surgery.

[248]  M. Pini,et al.  Seasonal Variation of Oral Anticoagulant Effect , 1994, Thrombosis and Haemostasis.

[249]  R. White,et al.  College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. , 1998, Archives of pathology & laboratory medicine.

[250]  P. Mannucci,et al.  Genetic control of anticoagulation , 1999, The Lancet.

[251]  S. Cosgriff.  The effectiveness of an oral vitamin K1 in controlling excessive hypoprothrombinemia during anticoagulant therapy. , 1956, Annals of internal medicine.

[252]  L Goldman,et al.  Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. , 1989, The American journal of medicine.

[253]  B. Rothschild.  Hematologic perturbations associated with salicylate , 1979, Clinical pharmacology and therapeutics.

[254]  A. Schirger,et al.  Small doses of vitamin K1 for correction of reduced prothrombin activity. , 1959, Proceedings of the staff meetings. Mayo Clinic.

[255]  R. O'Reilly,et al.  Warfarin metabolism and drug-drug interactions. , 1987, Advances in experimental medicine and biology.

[256]  L. Poller,et al.  An Evaluation of Chromogenic Substrates in the Control of Oral Anticoagulant Therapy , 1981, British journal of haematology.

[257]  R. O'Reilly.  Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. , 1980, The New England journal of medicine.

[258]  J. Howard,et al.  The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. , 1974, The Journal of biological chemistry.

[259]  W. Trager,et al.  Interaction of secobarbital with warfarin pseudoracemates , 1980, Clinical pharmacology and therapeutics.

[260]  J. Mohr,et al.  Antithrombotic Therapy for Cerebrovascular Disorders : An Update , 1995 .

[261]  G. Raskob,et al.  Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. , 1982, The New England journal of medicine.

[262]  R. Weibert,et al.  Potentiation of warfarin anticoagulation by topical testosterone ointment. , 1985, Clinical pharmacy.

[263]  K. High,et al.  Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer. , 1993, Archives of pathology & laboratory medicine.

[264]  G. Raskob,et al.  Hemorrhagic complications of anticoagulant treatment. , 1992, Chest.

[265]  M. Gibaldi,et al.  The warfarin‐sulfinpyrazone interaction: stereochemical considerations , 1986, Clinical pharmacology and therapeutics.

[266]  G. Albers,et al.  Stroke prevention in nonvalvular atrial fibrillation: A review of prospective randomized trials , 1991, Annals of neurology.

[267]  C. Gilroy,et al.  Acetaminophen and risk factors for excess anticoagulation with warfarin. , 1998, JAMA.

[268]  C. Mok,et al.  Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. , 1985, Circulation.

[269]  R. Marlar,et al.  Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. , 1997, American journal of clinical pathology.

[270]  J. Hirsh,et al.  Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy , 1997, Annals of Internal Medicine.

[271]  J. T. ten Cate,et al.  Results of a Multicenter Study Assessing the Status of Standardization of a Recombinant Thromboplastin for the Control of Oral Anticoagulant Therapy , 1994, Thrombosis and Haemostasis.

[272]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[273]  Bell Rg.  Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K--epoxide cycle. , 1978 .

[274]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[275]  J. Ansell,et al.  Management of oral anticoagulant therapy. Experience with an anticoagulation clinic. , 1984, Archives of internal medicine.

[276]  E. Ritz,et al.  Evidence for Impaired Hepatic Vitamin K1 Metabolism in Patients Treated with N-Methyl-Thiotetrazole Cephalosporins , 1984, Thrombosis and Haemostasis.

[277]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[278]  Vittorio Pengo,et al.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) , 1996, The Lancet.

[279]  I. Wright.  Recent developments in antithrombotic therapy. , 1969, Annals of internal medicine.

[280]  C. Bacon,et al.  Letter: Successful pregnancy in acute leukaemia. , 1975, Lancet.

[281]  Acetaminophen and risk factors for excess anticoagulation with warfarin. , 1998, JAMA.

[282]  Stroke Investigators.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study , 1994, The Lancet.

[283]  A. Cantor,et al.  Recognition site directing vitamin K-dependent γ-carboxylation resides on the propeptide of factor IX , 1987, Cell.

[284]  P. Mannucci,et al.  Are Capillary Whole Blood Coagulation Monitors Suitable for the Control of Oral Anticoagulant Treatment by the International Normalized Ratio? , 1993, Thrombosis and Haemostasis.

[285]  G. Seabrook,et al.  An outpatient anticoagulation protocol managed by a vascular nurse-clinician. , 1990, American journal of surgery.

[286]  B. Furie,et al.  Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. Conformation-specific antibodies directed against the phospholipid-binding site on prothrombin. , 1986, The Journal of biological chemistry.

[287]  R. Hall,et al.  Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. , 1995, European heart journal.

[288]  J. Cazenave,et al.  Effects of Penicillin G on Platelet Aggregation, Release, and Adherence to Collagen 1 , 1973, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[289]  M. Andrew,et al.  Decreased Thrombin Activity of Fibrin Clots Prepared in Cord Plasma Compared with Adult Plasma , 1996, Pediatric Research.

[290]  L. Poller.  THE EFFECT OF THE USE OF DIFFERENT TISSUE EXTRACTS ON ONE-STAGE PROTHROMBIN TIMES. , 1964, Acta haematologica.